scholarly journals Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone

2021 ◽  
Author(s):  
Thomas Römer ◽  
Johannes Bitzer ◽  
Christian Egarter ◽  
Peyman Hadji ◽  
Marion Kiechle ◽  
...  
Keyword(s):  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Current Status ◽  
Hormonal Contraceptives ◽  
Cardiovascular Side Effects ◽  
Administration Regimen ◽  
Vaginal Rings ◽  
Early Follicular Phase ◽  
Single Pill ◽  
The Usa

AbstractHormonal contraceptives are an effective and safe method for preventing pregnancy. Progestins used in contraception are either components of combined hormonal contraceptives (tablets, patches or vaginal rings) or are used as a single active ingredient in progestin mono-preparations (the progestin-only pill (POP), implants, intrauterine systems or depot preparations). Progestins are highly effective in long-term contraception when used properly, and have a very good safety profile with very few contraindications. A new oestrogen-free ovulation inhibitor (POP) has recently been authorised in the USA and the EU. This progestin mono-preparation contains 4 mg of drospirenone (DRSP), which has anti-gonadotropic, anti-mineralocorticoidic and anti-androgenic properties. The hormone administration regimen of 24 days followed by a 4-day hormone-free period was chosen to improve bleeding control and to maintain oestradiol concentrations at early follicular-phase levels, preventing oestrogen deficiency. Clinical trials have demonstrated a high contraceptive effectiveness, a very low risk of cardiovascular side effects and a favourable menstrual bleeding pattern. Due to the long half-life of DRSP (30 – 34 hours), the effectiveness of the preparation is maintained even if a woman forgets to take a pill on a single occasion. Studies involving deliberate 24-hour delays in taking a pill have demonstrated that ovulation inhibition is maintained if a single pill is missed. Following a summary of the current status of oestrogen-free contraception, this review article will describe the clinical development programme of the 4 mg DRSP mono-preparation and the resulting data on the effectiveness and safety of this new oestrogen-free oral hormonal contraceptive.

scholarly journals Contraception for the Cardiac Patient: a Cardiologist’s Primer

2020 ◽  
Vol 22 (12) ◽  
Author(s):  
Karen L. Florio ◽  
Monica Kao ◽  
Traci Johnson ◽  
Heidi A. Tuttle ◽  
Darcy White ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Hormonal Contraception ◽  
Significant Risk ◽  
Hormonal Contraceptive ◽  
Hormonal Contraceptives ◽  
Specific Recommendation ◽  
First Line Therapy ◽  
Unwanted Pregnancies ◽  
The Usa ◽  
Future Pregnancy

Abstract Purpose of review Cardiovascular disease (CVD) is the number one cause of maternal mortality in the USA. There are many cardiac conditions which pose significant risk to maternal health, and these women should be offered options to avoid unwanted pregnancies. Individualized contraceptive counseling focusing on woman’s desire for future pregnancy, comorbid conditions, and desire for hormone or non-hormonal (contraceptive) options is paramount to avoid adverse or unwanted side effects. The purpose of this review is to give general guidance on prescribing both hormonal and non-hormonal contraceptives for providers caring for women with heart disease. Recent findings Specific recommendation for the use of either non-hormonal or hormonal contraception requires knowledge of the types of contraceptive options available, cost, failure rates, and contraindications to use. Newer progestin-only options have become available and should be considered first-line therapy for women with cardiovascular disease. Summary The physiologic burden of pregnancy on the cardiovascular system can cause significant maternal morbidity and mortality for women with underlying CVD. These women should be offered safe and effective options for birth control, and both cardiology and obstetrical providers alike should possess fundamental knowledge of appropriate options.

scholarly journals Market Diffusion of Extended Cycle Hormonal Contraceptives

2012 ◽  
Vol 3 (3) ◽  
Author(s):  
Megen Leeds Schumacher ◽  
Ashley Cetola Pettia ◽  
Albert I Wertheimer
Keyword(s):  
Hormonal Contraception ◽  
Target Population ◽  
Hormonal Contraceptive ◽  
The United States ◽  
Hormonal Contraceptives ◽  
Original Research ◽  
Main Concern ◽  
Novel Approach ◽  
Market Diffusion ◽  
Extended Cycle

Background: Extended cycle hormonal contraceptives (e.g. Seasonale, Seasonique) when introduced in 2003 were considered a very novel approach to contraception. The idea of manipulating the menstrual cycle so that women would experience just four menstruations a year was radical and was assumed to be responsible for the slow acceptance rate among the general public. Objective: This report analyzes two different aspects of the acceptance of this unique idea in the population. The first was the level of usage of extended cycle hormonal contraceptives in the general population, which was measured by a review of sales figures over time in the United States. The second was an examination of market diffusion as it relates to consumer perceptions regarding the characteristics of these products. Methods: To determine the degree of usage of extended cycle hormonal contraceptives the yearly sales, in terms of units sold, were compared with that of other leading methods of hormonal contraception. Along with the data, survey answers were obtained from 65 women who volunteered to participate in the study. Participants were selected randomly to represent the target population to assess the level of awareness about the benefits, risks, and any other concerns regarding the use of extended cycle hormonal contraceptives. Results: The yearly sales data of units sold showed a definitive increase in the sales of extended cycle hormonal contraceptives since their release on the market. The survey results showed an overwhelming awareness in the study population about the extended regimen. However, only about half of the women in the survey group were aware of its benefits. The main concern reported was the perceived significant side effect profile. Conclusion: Though awareness about the extended cycle hormonal contraception regimen was widespread, the survey population was not well informed about the advantages and the disadvantages regarding the degree of severity of side effects. To address these knowledge deficits, these aspects should be the focus when distributing information about extended cycle hormonal contraceptive regimens. This may boost the use of a potentially advantageous contraceptive regimen by a population who would derive benefit from its usage.   Type: Original Research

scholarly journals Risk Factors of Body Mass Index (BMI), Age of Menarche, Parity and Hormonal Contraception of Genu Osteoarthritis in Female Patients

2021 ◽  
Vol 57 (2) ◽  
pp. 104
Author(s):  
Alisiya Alisiya ◽  
Sulistiawati Sulistiawati ◽  
Patricia Maria Kurniawati ◽  
RR Indrayuni Lukitra Wardhani
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Hormonal Contraceptives ◽  
Control Group ◽  
Case Group ◽  
Control Approach ◽  
Female Patients ◽  
Age Of Menarche

Osteoarthritis (OA) is a degenerative disease related to joint cartilage and commonly occurs in the knee joint. The 2013 National Survey recorded the prevalence of joint diseases in East Java was 26.9%. OA affected more women than men due to the estrogen and caused disabilities in many women. This study aimed to find the relationship between Body Mass Index (BMI), age of menarche, parity, and the use of hormonal contraceptives against OA in genu at Universitas Airlangga Hospital, Surabaya. This was an analytic observational study with a case-control approach. Data collection was carried out through a short interview using a questionnaire. The sample size was calculated using a formula and found that the study required 42 patients with OA in the case group and 42 patients without OA in the control group. The case group was dominated by patients with 56-60 years old age (62.1%), BMI 23-24.9 kg/m2 (58.7%), menarche age 12-13 years (53.6%), multiparous (52.6%), having contraception pill usage history (62.3%) particularly using combination pills (60.5%) with a mean duration of use > 1 year (56.8%). There was a relationship between BMI and type of hormonal contraceptive used against genu OA in female patients at Universitas Airlangga Hospital Surabaya.

scholarly journals PENGGUNAAN KONTRASEPSI HORMONAL DAN OBESITAS PADA WANITA USIA SUBUR DI INDONESIA: ANALISIS DATA IFLS 5 TAHUN 2014

2020 ◽  
Vol 10 (2) ◽  
pp. 101-110
Author(s):  
Yusri Kartika ◽  
Sudarto Ronoatmodjo
Keyword(s):  
Contraceptive Use ◽  
Cox Regression ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Reproductive Age ◽  
Hormonal Contraceptives ◽  
Bivariate Analysis ◽  
P Value ◽  
Cross Sectional ◽  
Reproductive Age Women

Abstract Background: Prevalence of obesity in adult females in Indonesia is 32,9% in 2013. Hormonal contraceptives (pills, injections and implants) are widely used by reproductive-age women in Indonesia, and the prevalence is 45%. Objective: The aim of this study is to identify whether reproductive-age women who use hormonal contraceptives are at risk of developing obesity compared to WUS who do not use hormonal contraceptives. Method: The design of this study is a cross sectional study using secondary data (5th Indonesia Family Life Survey, and the sample is reproductive-age women (15-49 years old) consisting of 6045 respondents. The variables of this study are obesity, hormonal contraceptive use, age, education, occupation, and duration of contraceptive use. Data were analysed by using Cox Regression. Result: The results of bivariate analysis showed that hormonal contaceptive use, age, education, occupation, and duration of contraceptive use were associated with obesity among reproductive-age womenand statistically significant (P-Value <0,05). Multivariate analysis showed that hormonal contraceptive use did not increase the risk of obesity among reproductive-age women in Indonesia (PR 0.939; CI 95% 0.869 - 1.013). Conclusion: The use of hormonal contraception did not increase the risk of obesity among reproductive-age women. Key words: Hormonal Contraception; Obesity; Reproductive Age-Women Abstrak Latar belakang : Prevalensi obesitas pada perempuan dewasa di Indonesia sebesar 32,9 persen pada tahun 2013. Kontrasepsi hormonal (pil, suntikan dan implan) merupakan jenis kontrasepsi yang paling banyak digunakan oleh wanita usia subur (WUS) di Indonesia, dengan prevalensi sebesar 45%. Tujuan : untuk mengetahui apakah wanita usia subur (WUS) yang menggunakan kontrasepsi hormonal berisiko mengalami obesitas dibandingkan WUS yang tidak menggunakan kontrasepsi hormonal.  Metode : Desain penelitian ini adalah studi cross- sectional dengan menggunakan data sekunder IFLS 5 tahun 2014. Sampel adalah WUS (15-49 tahun) sebanyak 6.045 responden. Variabel dalam penilitian ini adalah obesitas pada WUS, penggunaan kontrasepsi hormonal, umur, pendidikan, pekerjaan, serta lama penggunaan kontrasepsi. Analisis data yang digunakan adalah Cox Regression. Hasil : Hasil analisis bivariat menunjukkan bahwa variabel penggunaan kontrasepsi hormonal, umur, pendidikan dan status pekerjaan, serta  lama penggunaan kontrasepsi berhubungan dengan obesitas pada WUS (p-value <0,05). Analisis multivariat menunjukkan bahwa penggunaan kontrasepsi hormonal tidak meningkatkan risiko obesitas secara bermakna pada WUS di Indonesia (PR 0,939; CI 95% 0,869 – 1,013). Kesimpulan: Penggunaan kontrasepsi hormonal tidak meningkatkan risiko WUS untuk mengalami obesitas.   Kata kunci: Kontrasepsi Hormonal; Obesitas; Wanita Usia Subur

Recent Advances in Hormonal Contraceptives for Women

2008 ◽  
Vol 1 (3) ◽  
pp. 199-206
Author(s):  
D. Samba Reddy
Keyword(s):  
Birth Control ◽  
Oral Contraceptives ◽  
Hormonal Contraception ◽  
Daily Intake ◽  
Hormonal Contraceptive ◽  
Hormonal Contraceptives ◽  
Breakthrough Bleeding ◽  
Contraceptive Agents ◽  
Recent Advances ◽  
Hormone Injection

Currently, Contraceptive agents play a key role in family planning in India. Hormonal contraception is the marketed most common birth control option in women. An estimated 100 million women throughout the world use hormonal contraceptives for prevention of pregnancy. This article briefly describes the recent advances in hormonal contraceptive strategies that may minimize side effects while optimizing effective contraception. There are four types of hormonal contraceptive agents available for birth control. They include oral contraceptives pills (combined and mini-pills), contraceptive patches, hormonal implants, intrauterine devices and hormone injection agents. Oral contraceptives (OCs) are among the most widely used agents because they are highly effective when used properly. Generally, OCs are designed to simulate the 28 days of the menstrual cycle by daily intake of steroid hormones consisting of an estrogen and/or a progesterone. The primary mechanism underlying OC action is inhibition of ovulation. This action is achieved using a variety of OCs with substantially different components, doses, and side effect profile.  Two types of OC pills are widely available: combination pills; and progesterone only pills. The combined daily OC pill is composed of low dose of synthetic estrogen and progesterone. They are usually taken for 21 days with a 7 day gap during which menstruation-like bleeding occurs. Recently, there are several new OCs that have been approved to minimize the frequency and/or extent of breakthrough bleeding while achieving reliable means of contraception for the avoidance of unplanned pregnancies.

scholarly journals Studi Lama dan Jenis Kontrasepsi Hormonal yang Digunakan dengan Gangguan Menstruasi Akseptor KB Aktif di Wilayah Kerja Puskesmas Jati Raya Kota Kendari

bionature ◽  
2019 ◽  
Vol 20 (2) ◽  
pp. 123
Author(s):  
Amiruddin Amiruddin ◽  
Agriansyah A Agriansyah A ◽  
Risna Risna
Keyword(s):  
Family Planning ◽  
Health Center ◽  
Contraceptive Use ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Cross Sectional Study ◽  
Hormonal Contraceptives ◽  
Menstrual Disorders ◽  
Chi Square ◽  
Cross Sectional

Abstract. Based on initial observations on hormonal contraceptive KB acceptors in the working area of the Jati Raya Health Center in Kendari City, many acceptors experience menstrual disorders. This study aims to determine the relationship between duration of use and the type of hormonal contraception used with menstrual disorders inactive family planning acceptors in the working area of Jati Raya Health Center, Kendari City. This type of research is an association with the Cross-Sectional Study design. The population in this study was 153 acceptors. The sample was determined by purposive sampling of 138 respondents using a questionnaire. The results showed respondents with a duration of use <6 months (45.7%), 6 months - 1 year (31.2%), and> 1 year (23.2%), the type of hormonal contraception used is; injections (80.4%), pills (13.8%) and implants (5.8%), menstrual disorders before using hormonal contraceptives namely; normal (39.1%) and mild disorders (60.9%) and after using hormonal contraception, mild disorders (15.9%), moderate (39.1%) and severe (44.9%). The results of data analysis with the chi-square test concluded that the length of hormonal contraceptive use was significantly related to menstrual disorders in active KB acceptors in the working area of the Jati Raya Health Center in Kendari City and the type of hormonal contraception used was significantly related to menstrual disorders in active KB acceptors in the Puskesmas work area. Jati Raya Kendari City (p <0.05). Keywords: old, hormonal contraception, menstrual disorders, family planning acceptors.

scholarly journals Hormonal Contraceptive Use Related to Menopausal Age

2021 ◽  
Vol 2 (4) ◽  
pp. 214-218
Author(s):  
Destri Safhira Siahaan ◽  
Adek Amansyah ◽  
Irza Haicha Pratama
Keyword(s):  
Contraceptive Use ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
Primary Data ◽  
Hormonal Contraceptives ◽  
Research Subjects ◽  
Cross Sectional ◽  
Number Of Children ◽  
Menopausal Women ◽  
Cross Sectional Design

The change in the pattern and timing of menopause is an exciting and exploratory phenomenon that requires more detailed research to be carried out using hormonal contraception. This study was aimed to explore the relationship between hormonal contraceptive use and menopausal age. This study used a cross-sectional design. The study was conducted at Royal Prima General Hospital Medan from May to August 2021. A total of 68 research subjects participated in this study with the following inclusion criteria: menopausal women, aged 50-60 years, using hormonal contraceptives (pills, injections, implants), able to remember history previous contraceptive use. This study uses primary data obtained directly from guided interviews with respondents. Participants were dominated by ≥ 55 years old women with 57 people (83.81%), 62 Muslims (91.2%), menarche age >13 years as many as 28 people (41.2%). The number of children 2-4 were 32 people (47.1%) with an average menopause age of 51.93 and the smallest for 1 was 8 people (11.8%) with an average menopause age of 50.37. There were 49 users of hormonal contraception (72.1%) and 48 people (70.6%). In conclusion, we found that the use of hormonal contraceptives is significantly related to menopausal age.

Breaking down barriers to birth control access: An assessment of online platforms prescribing birth control in the USA

2019 ◽  
Vol 26 (6) ◽  
pp. 322-331 ◽  
Author(s):  
Carmela Zuniga ◽  
Daniel Grossman ◽  
Sara Harrell ◽  
Kelly Blanchard ◽  
Kate Grindlay
Keyword(s):  
Birth Control ◽  
Contraceptive Use ◽  
Insurance Coverage ◽  
Hormonal Contraception ◽  
Hormonal Contraceptives ◽  
Eligibility Criteria ◽  
Online Platforms ◽  
Significant Barrier ◽  
The Usa ◽  
Evidence Based Care

Introduction In the USA, the requirement that individuals obtain a prescription for hormonal contraception is a significant barrier for women who lack the time, finances, insurance coverage or means of transportation to visit a provider. The emergence of telemedicine services has removed some of these barriers by providing women with the opportunity to conveniently obtain birth control prescriptions through their computer or smartphone. Methods In this article, we compare the prescribing processes and policies of online platforms that prescribe hormonal contraceptives to women in the USA, and use the recommendations of the 2016 US medical eligibility criteria for contraceptive use to evaluate whether online prescribers are providing evidence-based care. Results As of February 2018, nine online platforms prescribed hormonal birth control to women across various states in the USA. These platforms varied in regard to their prescribing processes, range of methods offered, locations of operation, fees for services, and policies regarding age restrictions. Discussion An assessment of each platform’s online health questionnaire reveals that these telemedicine services are adequately screening for contraindications and safely providing birth control methods to patients, although efforts could be made to strengthen the rigour of online health questionnaires to ensure they adequately screen for all contraindications.

Clinical relevance in present day hormonal contraception

2018 ◽  
Vol 37 (1) ◽  
Author(s):  
Pedro-Antonio Regidor
Keyword(s):  
Ethinyl Estradiol ◽  
Hormonal Contraception ◽  
Active Agent ◽  
Hormonal Contraceptives ◽  
Therapeutic Effects ◽  
Mode Of Application ◽  
Ovulation Inhibition ◽  
Vaginal Rings ◽  
Long Acting ◽  
Combined Hormonal Contraceptives

Abstract The contraceptive pill is an effective and very safe method to control pregnancies. It was developed 60 years ago, and despite that the composition has been the same since it was first developed (estrogen and progestogen), over the years the concentration of ethinyl estradiol has been reduced to improve tolerability. Nevertheless, progestogens are the basic active agent of hormonal contraception. The mechanism of progestogens is a multimodal one and basically three modes of contraceptive action can be distinguished: (a) A strong antigonadotrophic action leading to the inhibition of ovulation. The necessary dosage of ovulation inhibition per day is a fixed dosage that is intrinsic to each progestogen and independent of the dosage of estrogen used or the partial activities of the progestogen or the mode of application. (b) Thickening of the cervical mucus to inhibit sperm penetration and (c) desynchronization of the endometrial changes necessary for implantation. The on the market available progestogens used for contraception are either used in combined hormonal contraceptives (in tablets, patches or vaginal rings) or as progestogen only contraceptives. Progestogen only contraceptives are available as daily oral preparations, monthly injections, implants (2–3 years) and intrauterine systems (IUS). Even the long-acting progestogens are highly effective in typical use and have a very low risk profile. According to their introduction into the market, progestogens in combined hormonal contraceptives, have been described as 1st, 2nd, 3rd and 4th generation progestogens. The different structures of progestogens are derivatives from testosterone, progesterone and spironolactone. These differences in the molecular structure determine pharmacodynamic and pharmacokinetic differential effects which contribute to the tolerability and additional beneficial or therapeutic effects whether used in combined oral contraceptive (COC) or as progestogen only drugs. These differences enhance the individual options for different patient profiles. The new development of polymers for vaginal rings allowed on the one hand, the improvement of the estrogen/progestogen combination in these rings especially regarding the comfort of use for women (e.g. avoiding the use of cold chains or packages with up to 6-month rings) and on the other hand, the development of progestogen only formulations. Another future development will be the introduction of new progestogen only pills that will provide effective contraceptive protection with more favorable bleeding patterns and a maintenance of ovulation inhibition after scheduled 24-h delays in pill intake than the existing progestogen only pill (POP) with desogestrel (DES).

scholarly journals Duration of Hormonal Contraception and Risk of Cervical Cancer

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Yuni Kusmiyati ◽  
Annisaputri Prasistyami ◽  
Heni Puji Wahyuningsih ◽  
Hesty Widyasih ◽  
Qorinah Estiningtyas Sakilah Adnani
Keyword(s):  
Cervical Cancer ◽  
Pap Smear ◽  
Contraceptive Use ◽  
Hormonal Contraception ◽  
Hormonal Contraceptive ◽  
The Body ◽  
Hormonal Contraceptives ◽  
P Value ◽  
Marriage Age ◽  
First Marriage

The use of long hormonal contraceptives can disrupt the balance of estrogen in the body, resulting in abnormal cell changes. This study aimed to determine a correlation between the duration of hormonal contraception and risk of cervical cancer. This study used a case-control design. The population  were patients who had examined at a cancer installation and obstetrics-gynecology polyclinic Dr. Sardjito Hospital in 2018. Case samples were 95 women have cervical cancer diagnosis and control were 95 women with a negative pap smear. Sampling with random sampling. Dependent variable cervical cancer and independent variable the duration of hormonal contraception are obtained from medical records. Cervical cancer is assessed by doctor’s diagnosis. Data analysis used logistic regression. Results showed that 44.7% of samples used long-term hormonal contraception (over 5 years). Length of use of hormonal contraception had a significant correlation with the incidence of cervical cancer (p-value < 0.01). Hormonal contraceptive use more than 5 years have a risk 4.2 times (95% CI 1.01-5.69) of cervical cancer than using less than 5 years after being controlled with the first marriage age and parity

Sign in / Sign up

Export Citation Format

Share Document